Head-to-head evidence
Amantadine ER (Gocovri/ADS-5102) vs AV-101
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: NMDA receptor · full Parkinson's Disease pipeline
Amantadine ER (Gocovri/ADS-5102)
Marketed by Supernus Pharmaceuticals and partners
NCT02136914 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 126 participants, with 63 assigned to ADS-5102 and 63 to placebo. The primary clinical endpoint was met: the week-12 UDysRS score decreased by 15.9 points with ADS-5102 versus 8.0 points with placebo, with a between-group difference of -7.9 points (p=0.0009).
AV-101
Developed by VistaGen Therapeutics
NCT04147949 · Phase 2 · status unknown
This is a small, randomized, double-blind, placebo-controlled crossover study using a validated dyskinesia rating scale as its primary measure. Results have not yet been posted, so the grade reflects only the well-controlled design in a modest number of participants.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Amantadine ER (Gocovri/ADS-5102)'s landscape · AV-101's landscape